2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2764

Incidence, Characteristics and Management of Giant Cell Arteritis in France: A Study Based on National Health Insurance Claims Data
Abstract Number: 2702

Incidence, Prevalence, Mortality and Comparison of the Acr/EULAR 2013 Classification Criteria with 1980 Criteria in Physician Diagnosed Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)
Abstract Number: 2283

Incidental Steroid Use May Worsen Outcomes in Patients with Heparin Induced Thrombocytopenia in the ICU Setting
Abstract Number: 2869

Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial
Abstract Number: 914

Increased Adverse Childhood Experiences in Children with Arthritis: An Analysis of the National Survey of Children’s Health
Abstract Number: 722

Increased Blood Pressure Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus: Association with Inflammation, Comorbidities and Increased Mortality
Abstract Number: 497

Increased Concentration of Large Very Low Density Lipoprotein Particles Associates with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 2255

Increased Cost Burden in an Early Diagnosed Cohort of Uncontrolled Versus Controlled Gout: Analysis of a Large US Payer Database
Abstract Number: 2898

Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Abstract Number: 1808

Increased Frequency of Obstructive Sleep Apnea Syndrome in Behcet’s Syndrome Patients with Vena Cava Superior Thrombosis
Abstract Number: 706

Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Abstract Number: 534

Increased Insulin Resistance and Impaired Beta-Cell Function in Patients with Rheumatoid Arthritis: The Role of Glucocorticoid Therapy?
Abstract Number: 2034

Increased Invasive Capacity and Metabolic Activity in Synovial Fibroblasts from Children with Downs Arthropathy Compared to Juvenile Idiopathic Arthritis
Abstract Number: 2896

Increased Mortality Among Patients with Systemic Lupus Erythematosus after Hydroxychloroquine Discontinuation
Abstract Number: 2696

Increased Mortality in Black and Asian Patients with Systemic Sclerosis in Northern California

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].